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Abstract
The biodistribution of long-circulating PEG-liposomes in a subcutaneous mouse model of established mixed infection
abscesses was investigated to assess their possible role as drug carriers in the treatment of small, undrainable intra-
abdominal abscesses. There was a 10^30-fold greater localisation of 67Ga-labelled PEG-liposomes in abscesses compared to
uninfected normal skin samples. Over 3% of the injected dose (ID) of liposomes was present in the abscesses 24 h after
liposome administration in contrast to 0.1% in normal skin sections. The percentage ID present in the liver, spleen and
kidneys was 17%, 4% and 2% per organ respectively. Five days after liposome injection, 2% ID could still be recovered
from the abscesses. Using colloidal gold-labelled PEG-liposomes, it was shown that there was a 4-fold greater density of
liposome clusters in the subcutaneous tissue surrounding the capsule than in the core of the abscesses. The clusters within
the abscesses were distributed evenly. We conclude that PEG-liposomes localise to a significant degree at the infection
focus in our mouse model and may provide a new approach to the antimicrobial treatment of intra-abdominal
abscesses. ß 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Despite improvements in the treatment of intra-
abdominal abscesses, high rates of morbidity and
mortality continue to be associated with these infec-
tions [1]. In our subcutaneous mouse model of estab-
lished mixed infection abscesses, we have shown that
treatment with broad-spectrum antimicrobials can
result in a signi¢cant reduction in bacterial counts
but only when very high doses were employed [2^4].
Treatment of established abscesses with antimicro-
bials encapsulated in long-circulating polyethylene
glycol-coated (PEG)-liposomes may o¡er an alterna-
tive, more e⁄cacious form of therapy. Previously, it
has been demonstrated in other experimental animal
models that these liposomes localise preferentially at
the in£ammatory sites of arthritis in rats [5], colitis in
rabbits [6], local bacterial thigh muscle infection in
rats [7], osteomyelitis in rabbits [8] and acute unilat-
eral pneumonia of the left lung in rats [9]. Further-
more, compared to the free form of an antibiotic,
therapeutic e⁄cacy can be enhanced [10^12] and
drug toxicity can be reduced [11,13] when antimicro-
bials are encapsulated in these liposomes.
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In this study, we have investigated the biodistribu-
tion of PEG-liposomes in the abscess model to assess
their possible role as drug carriers in the treatment of
small, undrainable intra-abdominal abscesses.
2. Materials and methods
2.1. Animals
Female speci¢ed pathogen free (SPF) BALB/c
mice (IFFA Credo, l’Arbresle, France) 12^18 weeks
and weighing 20^25 g were used throughout the
study. The caecal contents of male SPF Swiss mice
(Broekman Institute, The Netherlands) were used for
the production of autoclaved caecal contents (ACC)
[14]. All animals received water and food ad libitum.
The study was approved by the Institutional Animal
Care and Use Committee of the Erasmus University
(Rotterdam, The Netherlands).
2.2. Bacterial strains
Bacteroides fragilis ATCC 23745 and Escherichia
coli ATCC 25922 were used. Both strains were ¢rst
passaged in BALB/c mice and standardised bacterial
suspensions were made and stored at 380‡C until
required. Overnight cultures were obtained by inoc-
ulating 30 ml volumes of Wilkens Chalgren broth
(Boom, Meppel, The Netherlands) with 0.1 ml of
the standardised frozen bacterial suspensions and
incubating aerobically (E. coli) or anaerobically
(B. fragilis) at 37‡C for 18 h.
2.3. Mouse model
The subcutaneous abscess model has been de-
scribed previously [2]. Brie£y, mice were inoculated
(s.c.) on the right £ank with 0.25 ml mixtures con-
taining B. fragilis, 107 cfu, E. coli, 105 cfu, and ACC,
4 mg dry weight, in a ratio 1:1:2. The skin on the left
£ank was uninfected and used as a control. Vascular
permeability and biodistribution studies were per-
formed 3 days after inoculation on the established,
well-encapsulated abscesses that developed within the
subcutaneous tissue. Abscesses contained approx.
8 log10 cfu/abscess of both B. fragilis and E. coli
strains.
2.4. Vascular permeability
A quantitative test described by Zhang et al. [15]
was used to measure vascular permeability changes in
the abscesses. Three mice were inoculated on the right
£ank with B. fragilis/E. coli/ACC and, after 3 days,
were injected via the tail vein with a saline suspension
of Evans blue dye (40 mg/kg) (Merck, Darmstadt,
Germany). After 24 h, the mice were killed by CO2
asphyxiation and the complete pelt was removed. Ab-
scesses (including a section of surrounding skin) were
removed using an 18 mm punch and an identical
sized section of uninfected normal skin was similarly
dissected from the left £ank. The dye was extracted
from the tissues by placing the abscess and skin sec-
tions in 2 ml formamide (Sigma, St. Louis, MO,
USA) for 3 days. Absorbance was measured on an
LKB Ultrospec Plus spectrophotometer (Pharmacia,
Uppsala, Sweden) at a wavelength of 623 nm. Stan-
dards (0^20 Wg Evans blue/ml) were also dissolved in
formamide. Results were expressed as total Evans
blue (Wg) per abscess or skin section þ S.D.
2.5. Preparation and labelling of PEG-liposomes
PEG-liposomes were prepared as previously de-
scribed [9]. Brie£y, partially hydrogenated egg phos-
phatidylcholine (Asahi Chemical Industry, Ibaraki-
ken, Japan), cholesterol (Sigma) and 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine-N-(PEG-2000)
(Avanti Polar Lipids, Alabaster, AL, USA) were dis-
solved in chloroform:methanol in a round bottom
£ask in a molar ratio of 1.85:1:0.15, respectively.
After evaporation, the lipid mixture was redissolved
in 2-methyl-2-propanol (Sigma) and freeze dried
overnight. The dried lipids were hydrated for 2 h in
10 mM HEPES/135 mM NaCl (Sigma) bu¡er pH
7.4, containing 5 mM desferal (Novartis, Basel, Swit-
zerland). To obtain liposomes of approx. 100 nm, the
hydrated lipid dispersion was sonicated for 8 min in
a MSE Soniprep 150 (Sanyo Gallenkamp, Leicester,
UK). The liposomes were labelled with 67Ga-deferox-
amine as outlined by Schi¡elers et al. [16]. Previous
studies have shown 67Ga-deferoxamine to be an ap-
propriate label for monitoring intact liposomes in the
circulation because of the minimal translocation of
radioactive labels to plasma proteins and the rapid
renal clearance after release from the liposomes [17].
BBAMEM 78216 17-4-02 Cyaan Magenta Geel Zwart
L.E.T. Stearne et al. / Biochimica et Biophysica Acta 1561 (2002) 91^9792
2.6. Biodistribution studies
The 67Ga-labelled PEG-liposomes (100 Wmole total
lipid/kg) were administered i.v. via the tail vein to
groups of six mice 3 days after bacterial inoculation
of the right £ank. At 24 h, 48 h, 72 h or 120 h after
liposome injection, mice were killed by CO2 asphyx-
iation and the abscesses and normal skin sections
were removed as described in Section 2.4. The liver,
spleen and kidneys were also removed. The radioac-
tivity in the abscesses, skin and organs was counted
in a Minaxi autogamma 5000 Q-counter (Packard,
Meriden, CT, USA). The contribution of the radio-
activity in the blood was subtracted from the total
radioactivity measured in the abscesses, skin sections
and organs as described previously [16]. Results were
expressed as percentage injected dose (% ID) per
abscess, skin section or organ þ S.D. The correlation
between abscess weight and liposome localisation
24 h after injection was analysed by linear regression.
2.7. Preparation and tissue distribution of colloidal
gold-labelled PEG-liposomes
Colloidal gold-labelled PEG-liposomes were pre-
pared as described by Daemen et al. [18]. Brie£y,
the lipid ¢lm was prepared as outlined above and
hydrated at 4‡C with a ¢ltered (0.2 Wm) 1.1% (w/v)
aqueous solution of AuCl2 (Sigma) 4-fold diluted
with sodium citrate (28 mM)/potassium carbonate
(7 mM) bu¡er, pH 7.4. PEG-liposomes were sized
by sonication as described above. During sonication
the yellow suspension turned purple. Unencapsulated
colloidal gold was removed by gel ¢ltration of the
liposome suspension over a Sephacryl SF S1000 col-
umn (Pharmacia) using HEPES/NaCl bu¡er as the
eluent.
Two mice were injected i.v. with colloidal gold-
labelled PEG-liposomes (approx. 10 Wmol total lip-
id/kg) 3 days after bacterial inoculation. At 24 h after
liposome injection, abscesses were removed as de-
scribed previously, washed in three changes of 2.5%
bu¡ered formaldehyde (Merck), ¢xed in 10% bu¡-
ered formaldehyde and embedded in para⁄n. Sec-
tions of 5 Wm were cut on a microtome and mounted
on slides. Preparations were depara⁄nised in two
changes of xylene and hydrated. The colloidal gold-
labelled PEG-liposomes were silver-enhanced using a
silver enhancement kit (Sigma) according to the man-
ufacturer’s instructions. Eosin/haematoxylin was ap-
plied as a counterstain. Distribution of silver-en-
hanced colloidal gold clusters was evaluated by
counting the number of clusters present in sectors
measuring a total distance of 2.5 mm from the cap-
sule. Measurements were made both within the ab-
scess (capsuleCabscess core) as well as outside the
abscess (capsuleCsurrounding subcutaneous tissue).
Each sector was divided into 10 sub-sectors each
measuring 30 Wm2. In total, 40 di¡erent sectors
were measured from two di¡erent abscesses and the
results were expressed as mean number of clusters
counted per 30 Wm2 þ S.D.
2.8. Statistical analysis
Di¡erences in the vascular permeability and lipo-
some biodistribution between uninfected normal skin
compared to skin sections containing abscesses were
analysed by the paired t-test.
3. Results
3.1. Vascular permeability
Di¡erences in the vascular permeability of unin-
fected normal skin compared to skin sections con-
taining subcutaneous abscesses were determined in
mice by i.v. injection of Evans blue 3 days after bac-
terial inoculation. Unlike the normal skin, a distinct
Fig. 1. The vascular permeability of infected (abscess) and unin-
fected normal skin sections in mice. Evans blue dye (40 mg/kg)
was injected (i.v.) 3 days after inoculation (s.c.) with B. fragilis^
E. coli and, after 24 h, abscesses and normal skin sections were
removed. The mean Wg Evans blue per abscess or normal skin
section ( þ S.D.) is shown (n = 3, *P = 0.0008 compared to unin-
fected normal skin).
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dark blue zone was evident around the abscesses.
After formamide extraction of the dye, these di¡er-
ences were con¢rmed spectrophotometrically and in-
dicated a 4-fold di¡erence in the vascular permea-
bility between abscess and normal skin sections,
P = 0.0008 (Fig. 1).
3.2. Biodistribution of 67Ga-labelled PEG-liposomes
67Ga-labelled PEG-liposomes, injected 3 days after
bacterial inoculation, localised at the infectious focus
with a 10^30-fold greater liposome concentration in
the abscesses compared to normal skin sections (Fig.
2). Over 3% ID was present in the abscesses 24 h
after liposome injection compared to 0.1% in normal
skin (P = 0.0013). The % ID present in the liver,
spleen and kidneys at this time was 17 þ 3.4, 4 þ 0.6
and 2 þ 0.3% per organ respectively (results not
shown). Although abscess localisation gradually de-
Fig. 2. Biodistribution of 67Ga-labelled PEG-liposomes in in-
fected (abscess) and uninfected normal skin sections in mice.
Liposomes (100 Wmole/kg) were injected (i.v.) 3 days after bac-
terial inoculation (s.c.) with B. fragilis^E. coli and, after 24 h,
48 h, 72 h or 120 h, abscesses and normal skin sections were
removed. The mean % injected dose per abscess or normal skin
section ( þ S.D.) is shown (n = 6, *P = 0.0013, **P6 0.0001 com-
pared to uninfected normal skin).
Fig. 3. Correlation between abscess weight and liposome local-
isation 24 h after injection (i.v.) of 67Ga-labelled PEG-lipo-
somes. Each point represents an individual abscess.
Fig. 4. Tissue distribution of colloidal gold-labelled PEG-liposomes in abscesses. Liposomes (10 Wmole/kg) were injected (i.v.) 3 days
after bacterial inoculation (s.c.) with B. fragilis^E. coli and, after 24 h, abscesses were removed. Liposomes were stained with silver en-
hancement kit (see text) and counterstained with eosin/haematoxylin. Liposome clusters are shown as black specks both within the ab-
scess core and in the surrounding subcutaneous tissue (magni¢cation U400).
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creased over the following days, approx. 2% ID
could still be recovered from the site of infection
after 5 days. In addition, an increase in abscess
weight was also associated with a greater degree of
liposome localisation 24 h after injection (Fig. 3).
3.3. Distribution of colloidal gold-labelled
PEG-liposomes
Colloidal gold-labelled liposomes were used to
evaluate the tissue distribution of i.v. injected lipo-
somes at the cellular level. Micrographs showed an
abundance of silver-enhanced colloidal gold clusters
in the subcutaneous tissue surrounding the abscess
capsule (Fig. 4). Clusters were also present inside
the core of abscess, albeit at a lower density. Quan-
ti¢cation of the clusters in 30 Wm2 areas showed that
the capsule acted as a barrier to liposome penetration
(Fig. 5). The density of clusters was approx. 4-fold
higher in the surrounding subcutaneous tissue than
inside the core of the abscess. Within the capsule, the
clusters were distributed evenly.
4. Discussion
The aim of the present study was to investigate the
biodistribution of PEG-liposomes in our mouse
model to assess their possible role as drug carriers
in the treatment of small, undrainable intra-abdomi-
nal abscesses. Previous studies have shown that treat-
ment of these established abscesses is di⁄cult [3,4].
Very high doses of trova£oxacin (well into the range
of murine toxicity) were necessary to obtain more
than a 2 log10 cfu/abscess reduction of both bacterial
strains after 5 days of treatment [2]. These results
emphasise the need for a more e⁄cacious therapy
for these mixed infections.
One of the reasons for treatment failure of estab-
lished abscesses may be sub-e¡ective drug concentra-
tions at the site of infection and/or limited penetra-
tion of the antimicrobial into the core of the
abscesses [19]. In this respect, the encapsulation of
antibiotics in liposomes may be bene¢cial in the
treatment of these infections by altering the pharma-
cokinetics of the drug and enhancing therapeutic ef-
¢cacy [10^12,20] as well as reducing any potential
antibiotic toxicity [11,13]. PEG confers a steric stabil-
ity that reduces liposome uptake by the mononuclear
phagocytic system and results in a prolonged circu-
lation time and an improved liposome localisation at
in£ammatory sites [16,21^24]. Indeed, the PEG-lipo-
some blood concentration is the primary factor in£u-
encing the localisation of these liposomes at the site
of infection in a rat model of acute unilateral pneu-
monia [24]. Furthermore, when an antibiotic is lipo-
some-encapsulated, the doses and/or dosing fre-
quency required for an e¡ective treatment can be
reduced compared to the free form of a drug [10^12].
In the present study, the 10^30-fold higher degree
of liposome localisation at the site of the abscess
(over 3% ID) compared to normal skin illustrates
the targeting potential of PEG-liposomes in this
model. Furthermore, the liposome recovery from
the abscess, liver, spleen and kidneys was similar to
that found at the site of infection and organs in other
animal models [10,16]. The liposomes could be recov-
ered from the abscesses for a considerable period of
time (even at 5 days after injection). The preferential
localisation is probably due to the increased vascular
permeability facilitating local liposome extravasa-
tion. Increased capillary permeability has been re-
ported recently to play a crucial role in the localisa-
tion of PEG-liposomes in infected rat lung tissue
[25]. In addition, the positive linear relationship be-
tween abscess weight and liposome localisation sup-
Fig. 5. Distribution of silver-enhanced colloidal gold clusters in
sectors of 30 Wm2 measuring a total distance of 2.5 mm from
the capsule both within the abscess core and outside in the sur-
rounding subcutaneous (s.c.) tissue. Results are the mean þ S.D.
of 40 measurements per 30 Wm2 sector.
BBAMEM 78216 17-4-02 Cyaan Magenta Geel Zwart
L.E.T. Stearne et al. / Biochimica et Biophysica Acta 1561 (2002) 91^97 95
ports an earlier report by Bakker-Woudenberg et al.
[9] in which liposome localisation was linearly related
to infected left lung weight. Presumably, the intensity
of the in£ammatory response, which is a prerequisite
for liposome extravasation, is re£ected by the weight
(cell and £uid in£ux) at the site of infection.
Using colloidal gold-labelled liposomes, we have
shown that PEG-liposomes penetrate the capsule of
the abscess and are evenly distributed within the ab-
scess core. However, liposome localisation was sig-
ni¢cantly greater in the subcutaneous tissue sur-
rounding the abscess indicating the substantial
barrier imposed on liposome penetration by the cap-
sule. These results indicate that an antibiotic, if lipo-
some-encapsulated, would be delivered to a lesser
degree directly into the core of the abscess than in
the surrounding tissues. Nevertheless, the liposomes
remaining outside the capsule could be a source of
released antibiotic in the free form which could more
readily penetrate the abscess capsule.
The £uidity of the lipid bilayer is an important
determinant in the release of encapsulated antibiotics
from liposomes and, by varying liposome composi-
tion, a bilayer £uidity can be selected to ensure that
drug retention in the bloodstream and drug release at
the site of infection is optimised without compromis-
ing target localisation [16]. The potential of these
liposomes, therefore, to preferentially localise and
release e¡ective concentrations of an antibiotic with-
in the abscesses and surrounding tissues over a con-
siderable period of time provides an interesting pros-
pect for future studies and a possible new approach
to the antimicrobial treatment of intra-abdominal
abscesses.
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